PRODUCT DETAILS VIEW ALL PRODUCTS

Linosept Tablets and Infusion (Linezolid)

  • Each tablet contains linezolid 600 mg.Each vial contains 600mg in 300 ml infusion.
  • Complicated/uncomplicated skin & skin structure infections/community acquired pneumonia. For osteomyelitis in adults.
  • Linezolid inhibits bacterial protein synthesis through a mechanism of action different from that of other antibacterial agents; therefore, cross-resistance between linezolid and other classes of antibiotics is unlikely. Linezolid binds to a site on the bacterial 23S ribosomal RNA of the 50S subunit and prevents the formation of a functional 70S initiation complex, which is an essential component of the bacterial translation process.
  • 600 mg intravenously or orally every 12 hours.
  • Known hypersensitivity to linezolid or any of the other product components. Patients taking any monoamine oxidase inhibitors (MAOI) or within two weeks of taking an MAOI.
  • Myelosuppression: Monitor complete blood counts weekly. Consider discontinuation in patients who develop or have worsening myelosuppression. Peripheral and optic neuropathy: Reported primarily in patients treated for longer than 28 days. If patients experience symptoms of visual impairment, prompt ophthalmic evaluation is recommended. Serotonin syndrome: Discontinue serotonergic antidepressants and monitor patients for signs and symptoms of both serotonin syndrome and antidepressant discontinuation. Clostridioidesdifficile-Associated Diarrhea. Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. Phenylketonuria.
  • Pregnancy: Available data from published and postmarketing case reports with linezolid use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Nursing mother: The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for linezolid and any potential adverse effects on the breastfed child from linezolid or from the underlying maternal condition
  • Monoamine Oxidase Inhibitors: Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Adrenergic and Serotonergic Agents: Linezolid has the potential for interaction with adrenergic and serotonergic agents.
  • Most common adverse reactions (>5% of adult and/or pediatric patients treated with Linosept) include: diarrhea, vomiting, headache, nausea, and anemia.
  • Anti-Bacterials